REACT-2 study of coronavirus antibodies: June 2020 results
Results of real-time assessment of community transmission – prevalence of coronavirus (COVID-19) antibodies in June 2020.
Documents
Details
REACT-2 is the world’s largest surveillance study, undertaken in England, that examines the prevalence of antibodies in the community. The study focusses on finger prick self-testing at home by individuals aged 18 or over.
The findings will provide the government with a better understanding of the use of antibody tests at home as well as assess the trends in antibody levels and how they vary across different population subgroups.
This will inform government policies to protect health and save lives.
In this first round it used test results and feedback from 100,000 participants between 20 June to 13 July.
Read the pre-print version of this report
Read the press release accompanying these findings
Read the findings from REACT-2 Study 1 – Performance
Read the findings from REACT-2 Study 2 and 3 – Acceptance and usability
Further REACT-2 studies
REACT-2 – Vaccine uptake and SARS-CoV-2 antibody prevalence. Read the press release accompanying these findings.
REACT-2 Study 5 – Antibody survey and attitudes towards vaccines
This REACT-2 study shows over a third of people who had symptoms of coronavirus (COVID-19) reported symptoms lasting at least 12 weeks. Read the press release accompanying these findings.
REACT-2 – Behavioural responses to SARS-CoV-2 antibody testing in England
Last updated 11 August 2021 + show all updates
-
Added link to 'REACT-2 – Behavioural responses to SARS-CoV-2 antibody testing in England'.
-
Updated to add link to REACT 2 study 4 paper on Acceptability, usability and performance of lateral flow immunoassay tests for SARS-CoV-2 antibodies.
-
Added link to REACT 2 report on vaccine uptake and SARS-CoV-2 antibody prevalence.
-
First published.